Skip to content Skip to sidebar Skip to footer

Newsletter

Nick Sundich

1,252 articles published

Blue Chip Stocks

ASX 200 Winners: Here are 6 that have slipped under the radar

A quick glance of the list of ASX 200 Winners in 2025 would throw up many obvious candidates. The majority of companies are gold miners or developers. As of April 15, 2025, the list is topped by Spartan Resources (ASX:SPR) followed by Ora Banda (ASX:OBM) that have more than tripled in a year. Closely behind…

ByNick SundichApril 16, 20250Comments

Uranium Stocks

Will Trump Make Uranium Great Again? And either way, what’s next for uranium stocks

Uranium investors hoping the Trump administration would 'Make Uranium Great Again' have been disappointed so far, but should investors give up hope for another 4 years? Why the dream to Make Uranium Great Again hasn't come to fruition The hope that uranium would return to the pre-GFC glory days has been based on the assumption that…

ByNick SundichApril 16, 20250Comments

Gold Stocks Iron Ore Stocks Mining Stocks Rare Earths Stocks

MTM Critical Metals investors likely to benefit from Trump tariffs

MTM Critical Metals just might be a beneficiary from any 'Trump tariffs'. Investors in this company were facing an action-packed 2025 in front of them even in a more stable geopolitical environment. But the company could benefit, particularly from a 'worst case' scenario as far as Trump's tariffs are concerned (i.e. where most or all…

ByNick SundichApril 15, 20250Comments

Large Caps Mining Stocks Uncategorized

BHP shares have the ASX’s highest valuation at $180BN – but are they worth it?

BHP shares are the ASX's second most valuable, with the company capped at over A$180bn. Only CBA (ASX:CBA) usurps it, at just under $260bn, but only three other companies are valued above $100bn (CSL, Westpac and NAB if you were wondering). Rio Tinto for comparison is not even capped at $50bn. Who is BHP and why…

ByNick SundichApril 15, 20250Comments

Healthcare Stocks

Neuren Pharmaceuticals (ASX:NEU): Another exciting chapter is yet to come with NNZ-2591

Neuren Pharmaceuticals (ASX:NEU) is an ASX biotech company that has had a stellar past few years, but it is now facing the question: 'Where to now?' Companies with just one asset targeting one indication in just one jurisdiction can only go so far, and that is the step Neuren is at with Trofinetide.Its true that…

ByNick SundichApril 15, 20250Comments

Healthcare Stocks

CSL (ASX:CSL): Its promised double-digit earnings growth for the rest of the 2020s, but will Trump’s tariffs shatter the dream?

CSL has been hit more than most other stocks due to Trump tariffs. While many companies being sold off merely 'could' be impacted, this company almost certainly will be impacted. And if it is, the company's promise of 'double-digit earnings growth' for the rest of the decade might not be kept.CSL is the ASX's largest…

ByNick SundichApril 14, 20250Comments

Education

When do you know it’s time to ‘buy the dip’? You could be catching a falling knife

'Buy the dip' - have you ever heard that term? It implies that when a company's share price 'dips' or decreases, investor can make money by taking advantage of buying a company at a lower price.Theoretically, this is a good way to make money, but it is also a very risky way because a company's share…

ByNick SundichApril 14, 20250Comments

Education

Is free brokerage too good to be true? Here’s how stock brokers make money off you

Free brokerage is one of the key promises used by brokers to attract new clients. As one of the biggest costs of share trading, especially for prolific traders, this can sound appetising. But is this too good to be true? Yes and No.It is indeed correct that some brokers offer trading on international shares without…

ByNick SundichApril 11, 20250Comments

Tech Stocks Technology

Atturra (ASX:ATA): With a $53bn market opportunity, is this Australia’s next big tech star?

As a company that listed in 2021, Atturra (ASX:ATA) has performed much better than many would have thought. While many other IPOs during that year (the last of low interest rates worldwide) have crashed and burned, the opposite has been true of this company that listed with an ~$100m IPO and has nearly tripled since…

ByNick SundichApril 10, 20250Comments

Education

Here’s why stock investors turn to bonds during market crashes

Let's take a look at why stock investors turn to bonds. As they did during the Corona Crash, the GFC, the crash of 1987...and now. It is because bonds are perceived as a safe haven asset. But is this really the case? Why stock investors turn to bonds during market crashes: Safety First of all we'd…

ByNick SundichApril 10, 20250Comments

the Kick-ass Multipurpose WordPress Theme

Nick Sundich

ASX 200 Winners: Here are 6 that have slipped under the radar

Will Trump Make Uranium Great Again? And either way, what’s next for uranium stocks

MTM Critical Metals investors likely to benefit from Trump tariffs

BHP shares have the ASX’s highest valuation at $180BN – but are they worth it?

Neuren Pharmaceuticals (ASX:NEU): Another exciting chapter is yet to come with NNZ-2591

CSL (ASX:CSL): Its promised double-digit earnings growth for the rest of the 2020s, but will Trump’s tariffs shatter the dream?

When do you know it’s time to ‘buy the dip’? You could be catching a falling knife

Is free brokerage too good to be true? Here’s how stock brokers make money off you

Atturra (ASX:ATA): With a $53bn market opportunity, is this Australia’s next big tech star?

Here’s why stock investors turn to bonds during market crashes

Stocks in Spotlight

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Nick Sundich

Stocks in Spotlight

Add Your Heading Text Here